A new, innovative, and safe treatment in vitiligo: Results of a randomized, double‐blinded, parallel‐group study

Vitiligo is a chronic autoimmune disease affecting around 1% of the population worldwide. No existing treatment is giving fully satisfactory results. Further investigations are welcomed for innovative and safe treatments bringing better results. This trial aimed to compare the efficacy and tolerance of various treatment protocols on vitiligo lesions. Four randomized groups of 10 patients with vitiligo covering 8% to 14% of skin surface, except hands and feet were assigned during 8 weeks to (a) UVB microphototherapy 300 to 320 nm (Bioskin‒) 1 x week; (b) VITILSI‒ gel 2 x day; (c) VITILSI‒ gel 2xday + Bioskin‒ 1 x week; and (d) placebo 2 x day. Efficacy of the treatment was assessed by planimetry, comparing the photographs of the patients taken at baseline and after 8‐week treatment. After completion of the treatment, the increase of the pigment area was 28% in G1 (Bioskin‒), 19% in G2 (VITILSI‒), 41% in G3 (Bioskin‒ + VITILSI‒) and null in G4. No subject stopped the treatment and no side effect was observed. It was demonstrated that the gel under study was able per se to induce repigmentation in vitiligo lesions and that the results were significantly better when combined with NB‐UVB. The protocols used in this trial resulted safe and efficient.